Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

AMT-060 gene therapy provides long-term factor IX activity in hemophilia B patients

Feb. 10, 2020

Thrombosis leads to early termination of phase II BAY-1093884 trial

Feb. 10, 2020

First-in-human data show safety and early hemostatic efficacy of BAY-2599023

Feb. 10, 2020

Verseon divulges new thrombin inhibitors

Feb. 4, 2020

Initial first-in-human data presented for OTL-102

Feb. 4, 2020

Bayer presents data from the phase II FOXTROT study of osocimab

Feb. 3, 2020

Janssen presents phase II results for daratumumab in relapsed AL amyloidosis

Jan. 29, 2020

Results from phase I/II COMPOSER study of crovalimab

Jan. 29, 2020

Young blood not all it's cracked up to be

Jan. 22, 2020

Long-term safety and efficacy of AAV5-hFVIII-SQ gene therapy

Jan. 17, 2020

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...